Relapsed or refractory non-Hodgkin lymphoma
Clinical trials for Relapsed or refractory non-Hodgkin lymphoma explained in plain language.
Never miss a new study
Get alerted when new Relapsed or refractory non-Hodgkin lymphoma trials appear
Sign up with your email to follow new studies for Relapsed or refractory non-Hodgkin lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental drug YH004 put to the test in Hard-to-Treat cancers
Disease control CompletedResearchers are running a phase 1 trial of YH004, an experimental drug given intravenously every three weeks, in people with advanced solid tumors or relapsed or refractory non-Hodgkin lymphoma. The main goal is to find out whether YH004 is safe and tolerable, and to determine th…
Matched conditions: RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA
Phase 1 • Sponsor: Eucure (Beijing) Biopharma Co., Ltd • Aim: Disease control
Last updated Sep 22, 2026 20:01 UTC
-
Can a Two-Antibody combo supercharge the immune system against Hard-to-Treat cancers?
Disease control CompletedResearchers are testing an experimental antibody called YH004 in adults with advanced solid tumors or non-Hodgkin lymphoma that has come back or stopped responding to treatment. YH004 is designed to activate immune cells by targeting a protein called 4-1BB. The study gives YH004 …
Matched conditions: RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA
Phase 1 • Sponsor: Eucure (Beijing) Biopharma Co., Ltd • Aim: Disease control
Last updated Sep 22, 2026 20:01 UTC